Table 2.
Clinical characteristic of KPC-K.pneumoniae BSI
| Period 1: March 2012–Dec 2013 N 18 |
Period 2: Jan 2017–Oct 2018 N 16 |
p-value (absolute difference; 95% CI) | |
|---|---|---|---|
| KPC-K.pneumoniae BSI onset | |||
| -Shock | 10 (56%) | 7 (44%) | 0.73 (0.12; -0.21 to 0.45) |
| -Neutropenia | |||
| < 1000 neutrophils/cmm | 18 (100%) | 16 (100%) | |
| < 100 neutrophils/cmm | 14 (78%) | 15 (94%) | 0.40 (-0.16; -0.38 to 0.06) |
| -BSI developing under inactive antibiotic treatment | 11 (61%) | 0 | < 0.01 (0.61; 0.38 to 0.83) |
| Initial active treatment | 10 (56%) | 16 (100%) | < 0.01 (-0.44; -0.67 to -0.21) |
| -Combination | 7 (39%) | 15 (94%) | < 0.01 (-0.54; -0.80 to -0.29) |
| with colistin | 7 (39%) | 4 (25%) | 0.31 (0.13; -0.17 to 0.44) |
| with ceftazidime-avibactam | 0 | 11 (69%) | < 0.01 (-0.68; -0.91 to -0.46) |
| -Monotherapy | 3 (17%) | 1 (6%) | 0.34 (0.11; -0.10 to 0.31) |
| Tigecyclina | 3 (17%) | 0 | 0.13 (0.17; -0.005 to 0.33) |
| Ceftazidime/avibactam | 0 | 1 (6%) | 0.47;(-0.06; -0.18 to 0.05) |
| Fatal KPC-K.pneumoniae BSI | 9 (50%) | 1(6%) | < 0.01 (0.44; 0.17 to 0.69) |
| -Death within 96 h | 4 (22%) | 0 | 0.06 (0.22; 0.03 to 0.41) |
| -Shock | 7 (39%) | 0 | < 0.01 (0.39; 0.16 to 0.61) |
| -BSI developing during inactive antibiotic treatment | 8 (44%) | 0 | < 0.01 (0.44; 0.21 to 0.67) |
| -Inactive initial treatment | 7 (39%) | 0 | < 0.01 (0.39; 0.16 to 0.61) |
| -Acute myeloid leukemia | 7 (39%) | 1 (6%) | < 0.01 (0.33; 0.07 to 0.58) |
aCombined with piperacillin/tazobactam as empiric treatment of febrile neutropenia [14]